Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States

被引:57
作者
Cao, Pianpian [1 ]
Jeon, Jihyoun [1 ]
Levy, David T. [2 ]
Jayasekera, Jinani C. [2 ]
Cadham, Christopher J. [2 ]
Mandelblatt, Jeanne S. [2 ]
Taylor, Kathryn L. [2 ]
Meza, Rafael [1 ]
机构
[1] Univ Michigan, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48105 USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Canc Prevent & Control Program, Washington, DC USA
关键词
Lung cancer screening; Smoking cessation interventions; Lung and tobacco-related mortality; Cancer Intervention and Surveillance Modeling Network (CISNET); SMOKING-CESSATION; COST-EFFECTIVENESS; TOBACCO-CESSATION; OUTCOMES; COHORT; NLST;
D O I
10.1016/j.jtho.2020.02.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Annual lung cancer screening with low-dose computed tomography is recommended for adults aged 55 to 80 years with a greater than or equal to 30 pack-year smoking history who currently smoke or quit within the past 15 years. The 50% who are current smokers should be offered cessation interventions, but information about the impact of adding cessation to screening is limited. Methods: We used an established lung cancer simulation model to compare the effects on mortality of a hypothetical one-time cessation intervention and annual screening versus annual screening only among screen-eligible individuals born in 1950 or 1960. Model inputs were derived from national data and included smoking history, probability of quitting with and without intervention, lung cancer risk and treat-ment effectiveness, and competing tobacco-related mortality. We tested the sensitivity of results under different assump-tions about screening use and cessation efficacy. Results: Smoking cessation reduces lung cancer mortality and delays overall deaths versus screening only across all assumptions. For example, if screening was used by 30% of screen-eligible individuals born in 1950, adding an inter-vention with a 10% quit probability reduces lung cancer deaths by 14% and increases life years gained by 81% compared with screening alone. The magnitude of cessation bene fits varied under screening uptake rates, cessation effectiveness, and birth cohort. Conclusions: Smoking cessation interventions have the potential to greatly enhance the impact of lung cancer screening programs. Evaluation of specific interventions, including costs and feasibility of implementation and dissemination, is needed to determine the best possible strategies and realize the full promise of lung cancer screening. (C) 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1169
页数:10
相关论文
共 46 条
[1]   Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].
Aberle, Denise R. ;
Adams, Amanda M. ;
Berg, Christine D. ;
Black, William C. ;
Clapp, Jonathan D. ;
Fagerstrom, Richard M. ;
Gareen, Ilana F. ;
Gatsonis, Constantine ;
Marcus, Pamela M. ;
Sicks, JoRean D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409
[2]   Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers [J].
Aldrich, Melinda C. ;
Mercaldo, Sarah F. ;
Sandler, Kim L. ;
Blot, William J. ;
Grogan, Eric L. ;
Blume, Jeffrey D. .
JAMA ONCOLOGY, 2019, 5 (09) :1318-1324
[3]   Data Resource Profile: The Human Mortality Database (HMD) [J].
Barbieri, Magali ;
Wilmoth, John R. ;
Shkolnikov, Vladimir M. ;
Glei, Dana ;
Jasilionis, Domantas ;
Jdanov, Dmitri ;
Boe, Carl ;
Riffe, Timothy ;
Grigoriev, Pavel ;
Winant, Celeste .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 (05) :1549-1556
[4]   Cost-Effectiveness of CT Screening in the National Lung Screening Trial [J].
Black, William C. ;
Gareen, Ilana F. ;
Soneji, Samir S. ;
Sicks, JoRean D. ;
Keeler, Emmett B. ;
Aberle, Denise R. ;
Naeim, Arash ;
Church, Timothy R. ;
Silvestri, Gerard A. ;
Gorelick, Jeremy ;
Gatsonis, Constantine .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) :1793-1802
[5]  
Blewett LynnA., 2019, IPUMS HLTH SURVEYS N
[6]   Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer [J].
Bradley, Cathy J. ;
Eguchi, Megan ;
Perraillon, Marcelo C. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (08) :802-809
[7]  
Burns D., 1997, Changes in cigarette-related diseases risks and their implication for prevention and control [monograph no. 8], P113
[8]   Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis [J].
Cadham, Christopher J. ;
Jayasekera, Jinani C. ;
Advani, Shailesh M. ;
Fallon, Shelby J. ;
Stephens, Jennifer L. ;
Braithwaite, Dejana ;
Jeon, Jihyoun ;
Cao, Pianpian ;
Levy, David T. ;
Meza, Rafael ;
Taylor, Kathryn L. ;
Mandelblatt, Jeanne S. .
LUNG CANCER, 2019, 135 :205-216
[9]   The American Cancer Society cancer prevention study II nutrition cohort - Rationale, study design, and baseline characteristics [J].
Calle, EE ;
Rodriguez, C ;
Jacobs, EJ ;
Almon, ML ;
Chao, A ;
McCullough, ML ;
Feigelson, HS ;
Thun, MJ .
CANCER, 2002, 94 (09) :2490-2501
[10]  
Caverly TJ, 2018, ANN INTERN MED, V169, P1, DOI [10.7326/M17-2561, 10.7326/m17-2561]